POSEIDON: A phase 3 study of first-line Durvalumab +/- Tremelimumab plus chemotherapy vs chemotherapy alone in metastatic NSCLC
Journal article published in 2018 by
M. Thomas,
C. Grohe,
W. Eberhardt,
J. Rawluk,
M. Reck,
E. Laack,
C. Wesseler 
,
A. Rittmeyer,
J. Alt,
N. Reinmuth,
F. Griesinger,
J. Kern
,
A. Rittmeyer,
J. Alt,
N. Reinmuth,
F. Griesinger,
J. Kern
